Biogen (BIIB) Other Non-Current Assets (2009 - 2026)
Biogen (BIIB) posted quarterly Other Non-Current Assets of $831.8 million for Q2 2026, up 30.44% year-over-year from $637.7 million in Q2 2025, and up 6.98% quarter-over-quarter from $777.5 million in Q1 2026.
Biogen (BIIB) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Biogen's Other Non-Current Assets history runs 18 years deep, the most recent figure standing at $831.8 million for Q2 2026.
- In Q2 2026, Other Non-Current Assets rose 30.44% year-over-year to $831.8 million; the TTM figure through Jun 2026 stood at $831.8 million (up 30.44% YoY), while the FY2025 annual figure was $750.6 million, up 33.92% from the prior year.
- Other Non-Current Assets for Q2 2026 stood at $831.8 million, up from $777.5 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $1.8 billion in Q1 2022, with the low at $559.1 million in Q1 2025.
- The 5-year median for Other Non-Current Assets is $752.6 million (2023), against an average of $958.5 million.
- The sharpest annual moves came in 2023 and 2026: Other Non-Current Assets tumbled 53.21% in 2023, then jumped 39.06% in 2026.
- Biogen's Other Non-Current Assets stood at $1.5 billion in 2022, then slumped by 51.28% to $745.0 million in 2023, then declined by 24.77% to $560.5 million in 2024, then jumped by 33.92% to $750.6 million in 2025, then advanced by 10.82% to $831.8 million in 2026.
- Business Quant data shows BIIB's Other Non-Current Assets at $831.8 million in Q2 2026, $777.5 million in Q1 2026, and $750.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 14.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 10.73 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 19.60 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.93 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 12.98 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 4.75 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 9.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 3.56 Bn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | 831.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 831.80 Mn |
| Mar 31, 2026 | 777.50 Mn |
| Dec 31, 2025 | 750.60 Mn |
| Sep 30, 2025 | 729.70 Mn |
| Jun 30, 2025 | 637.70 Mn |
| Mar 31, 2025 | 559.10 Mn |
| Dec 31, 2024 | 560.50 Mn |
| Sep 30, 2024 | 631.40 Mn |
| Jun 30, 2024 | 681.50 Mn |
| Mar 31, 2024 | 697.60 Mn |
| Dec 31, 2023 | 745.00 Mn |
| Sep 30, 2023 | 754.60 Mn |
| Jun 30, 2023 | 1.10 Bn |
| Mar 31, 2023 | 1.38 Bn |
| Dec 31, 2022 | 1.53 Bn |
| Sep 30, 2022 | 1.61 Bn |
| Jun 30, 2022 | 1.50 Bn |
| Mar 31, 2022 | 1.77 Bn |
| Dec 31, 2021 | 1.94 Bn |
| Sep 30, 2021 | 2.02 Bn |